CAS Number: 83905-01-5
Zithromax | 83905-01-5
Zithromax (azithromycin), the first azalide macrolide antibiotic, is distinguished by its rapid and extensive penetration into intracellular and interstitial tissues, resulting in prolonged tissue and serum half-lives that enable short-course, once-daily dosing regimens. It demonstrates potent activity against both gram-positive and, notably, gram-negative pathogens, including Chlamydia trachomatis, Haemophilus influenzae, and *Moraxella catarrhalis. A single 1 g oral dose is highly effective and well tolerated for treating uncomplicated urethritis and cervicitis caused by C. trachomatis, as recommended by the CDC, while a 5-day regimen is approved for community-acquired respiratory tract infections and skin and skin-structure infections. Although generally well tolerated with fewer gastrointestinal side effects than erythromycin and classified as pregnancy category B, azithromycin must be used with caution in patients with cardiac risk factors due to possible QT prolongation, and like all antibiotics, its misuse promotes bacterial resistance. While generic versions such as Azithral are available, some quality and bioequivalence studies suggest that originator Zithromax tablets may demonstrate more satisfactory pharmaco-technical performance.
Product Information
HM Chemical Trading GmbH supplies industrial-grade specialty chemicals and raw materials with reliable international logistics support.
References
-
Efficacy and bioequivalence study of Zithromax and Azithral a drug for the treatment of COVID-19
Generic drugs are increasingly marketed around the world to the detriment of their quality. The objective of this work was therefore to carry out a bioequivalence study between the originator Zithromax, a drug for the treatment COVID-19, and its generic Azithral. This bioequivalence study is based on the quality control of generic and originator azithromycin tablets, which is carried out after validation of the azithromycin assay method, and essentially on pharmaco-technical tests (mass uniformity, breakability, disintegration, dissolution in vitro). By referring mainly to different pharmacopoeias, the tests have shown that the quality of generic tablets is acceptable but seems to be less satisfactory than that of originator tablets.
DOI: 10.1504/IJMEI.2026.151767 -
Azithromycin (Zithromax®)
Azithromycin (Zithromax®, Pfizer, Inc., New York, NY) is a 15-membered-ring macrolide and the first azalide antibiotic. It is distinguished from other macrolides by its rapid and extensive penetration into intracellular and interstitial tissue compartments, accompanied by prolonged tissue and serum half-lives. Azithromycin shares the gram-positive activity of erythromycin but is more potent against gram-negative organisms. For urethritis and cervicitis caused by Chlamydia trachomatis, azithromycin is effective and well tolerated in a single dose of 1 g, a regimen recommended by the CDC. A 5-day dosage regimen is available for the treatment of community-acquired respiratory-tract and skin and skin-structure infections caused by susceptible organisms. Azithromycin provides short-duration, high-compliance, cost-effective regimens that should improve outcomes.
Source: Infectious Diseases in Obstetrics and Gynecology